
    
      The protocol has been designed for relapsing or refractory multiple myeloma patients. A
      maximum of 30 patients may be treated on this protocol.

      Since this is a compassionate use study of an investigational agent, the size is determined
      by agreement with the manufacturer of carfilzomib. Therefore, the time period for enrollment
      and accrual number will be limited to N=30.
    
  